-
Tytuł:
-
Fibroblast Growth Factor 23 and Risk of New Onset Heart Failure With Preserved or Reduced Ejection Fraction: The PREVEND Study.
-
Autorzy:
-
Binnenmars SH; Department of Internal Medicine, Division of Nephrology University of Groningen, University Medical Center Groningen Groningen The Netherlands.
Hoogslag GE; Department of Internal Medicine, Division of Nephrology University of Groningen, University Medical Center Groningen Groningen The Netherlands.
Yeung SMH; Department of Internal Medicine, Division of Nephrology University of Groningen, University Medical Center Groningen Groningen The Netherlands.
Brouwers FP; Department of Cardiology University of Groningen, University Medical Center Groningen Groningen The Netherlands.
Bakker SJL; Department of Internal Medicine, Division of Nephrology University of Groningen, University Medical Center Groningen Groningen The Netherlands.
van Gilst WH; Department of Cardiology University of Groningen, University Medical Center Groningen Groningen The Netherlands.
Gansevoort RT; Department of Internal Medicine, Division of Nephrology University of Groningen, University Medical Center Groningen Groningen The Netherlands.
Navis G; Department of Internal Medicine, Division of Nephrology University of Groningen, University Medical Center Groningen Groningen The Netherlands.
Voors AA; Department of Cardiology University of Groningen, University Medical Center Groningen Groningen The Netherlands.
de Borst MH; Department of Internal Medicine, Division of Nephrology University of Groningen, University Medical Center Groningen Groningen The Netherlands.
-
Źródło:
-
Journal of the American Heart Association [J Am Heart Assoc] 2022 Aug 02; Vol. 11 (15), pp. e024952. Date of Electronic Publication: 2022 Jul 25.
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: Oxford : Wiley-Blackwell
-
MeSH Terms:
-
Fibroblast Growth Factor-23*
Heart Failure*/diagnosis
Heart Failure*/epidemiology
Adult ; Aged ; Cross-Sectional Studies ; Female ; Humans ; Male ; Middle Aged ; Prognosis ; Prospective Studies ; Risk Factors ; Stroke Volume
-
References:
-
Am J Nephrol. 2019;49(3):203-211. (PMID: 30808827)
J Clin Endocrinol Metab. 2014 Mar;99(3):947-55. (PMID: 24423292)
J Card Fail. 2013 Oct;19(10):692-711. (PMID: 24125108)
J Card Fail. 2005 Mar;11(2):99-105. (PMID: 15732028)
Ann Intern Med. 2010 May 18;152(10):640-8. (PMID: 20479029)
Hypertension. 2015 Sep;66(3):563-70. (PMID: 26195480)
BMC Med Res Methodol. 2010 Dec 31;10:112. (PMID: 21194416)
J Bone Miner Res. 1990 May;5(5):469-74. (PMID: 2368628)
PLoS Med. 2019 Jun 6;16(6):e1002818. (PMID: 31170159)
J Am Soc Nephrol. 2014 Feb;25(2):349-60. (PMID: 24158986)
Nat Rev Nephrol. 2014 May;10(5):268-78. (PMID: 24686452)
J Am Heart Assoc. 2014 Jun 10;3(3):e000936. (PMID: 24922628)
Int J Cardiol. 2014 Dec 15;177(2):575-7. (PMID: 25194866)
PLoS One. 2017 May 5;12(5):e0176984. (PMID: 28475601)
Oncotarget. 2016 Oct 4;7(40):64649-64664. (PMID: 27579618)
Int J Cardiovasc Imaging. 2014 Feb;30(2):349-56. (PMID: 24293047)
Ann Clin Biochem. 2009 Jul;46(Pt 4):338-40. (PMID: 19564163)
Int J Cardiol. 2018 Feb 15;253:84-90. (PMID: 29306478)
PLoS One. 2015 Jul 20;10(7):e0133580. (PMID: 26193703)
Nephrol Dial Transplant. 2016 Jul;31(7):1088-99. (PMID: 26681731)
Atherosclerosis. 2017 Jun;261:1-11. (PMID: 28411494)
J Clin Endocrinol Metab. 1997 Aug;82(8):2450-4. (PMID: 9253316)
J Am Soc Nephrol. 2007 Apr;18(4):1307-15. (PMID: 17344421)
Circ Heart Fail. 2014 Sep;7(5):723-31. (PMID: 25057112)
J Am Soc Nephrol. 2011 Sep;22(9):1603-9. (PMID: 21852584)
EMBO Mol Med. 2014 May 05;6(6):744-59. (PMID: 24797667)
Nephrol Dial Transplant. 2016 Sep;31(9):1494-501. (PMID: 26602863)
J Am Heart Assoc. 2018 Sep 18;7(18):e008334. (PMID: 30371180)
JACC Heart Fail. 2015 Jun;3(6):445-455. (PMID: 25982111)
Nephrol Dial Transplant. 2013 Sep;28(9):2228-36. (PMID: 23625971)
Physiol Rep. 2018 Apr;6(7):e13591. (PMID: 29611320)
J Am Soc Nephrol. 2017 Dec;28(12):3639-3646. (PMID: 28774998)
Eur Heart J. 2011 Nov;32(21):2688-96. (PMID: 21733911)
Stat Med. 2009 Jul 10;28(15):1982-98. (PMID: 19452569)
Kidney Int. 2016 Nov;90(5):985-996. (PMID: 27457912)
Heart. 2017 Jun;103(11):856-862. (PMID: 27979879)
Eur J Heart Fail. 2010 Aug;12(8):812-8. (PMID: 20675668)
Circulation. 2005 Oct 25;112(17):2627-33. (PMID: 16246962)
Circ Res. 2021 May 28;128(11):1616-1625. (PMID: 33825489)
J Am Soc Nephrol. 2000 Oct;11(10):1882-1888. (PMID: 11004219)
Circ Heart Fail. 2014 May;7(3):409-17. (PMID: 24668259)
Ann Intern Med. 2009 May 5;150(9):604-12. (PMID: 19414839)
Am J Physiol Heart Circ Physiol. 2018 Nov 1;315(5):H1414-H1424. (PMID: 30028196)
Bone. 2017 May;98:1-8. (PMID: 28212898)
Eur Heart J. 2013 May;34(19):1424-31. (PMID: 23470495)
J Clin Invest. 2016 Mar 1;126(3):962-74. (PMID: 26878171)
Cell Metab. 2015 Dec 1;22(6):1020-32. (PMID: 26437603)
Nephrol Dial Transplant. 2012 Dec;27(12):4314-22. (PMID: 22885518)
J Am Coll Cardiol. 2012 Jul 17;60(3):200-7. (PMID: 22703926)
Heart Vessels. 2016 Jan;31(1):66-73. (PMID: 25223536)
J Heart Lung Transplant. 2015 Sep;34(9):1211-4. (PMID: 26267742)
Am Heart J. 1994 Mar;127(3):674-82. (PMID: 8122618)
Eur Heart J. 2010 Jan;31(1):120-7. (PMID: 19854731)
Circulation. 2015 Jul 7;132(1):27-39. (PMID: 26059012)
J Clin Invest. 2011 Nov;121(11):4393-408. (PMID: 21985788)
J Intern Med. 2001 Jun;249(6):519-26. (PMID: 11422658)
Science. 2006 Mar 24;311(5768):1770-3. (PMID: 16497887)
Atherosclerosis. 2009 Aug;205(2):385-90. (PMID: 19181315)
J Bone Miner Res. 2015 Oct;30(10):1831-9. (PMID: 25858796)
Kidney Int. 2008 Aug;74(4):505-12. (PMID: 18496511)
Am Heart J. 2015 Jan;169(1):94-101.e2. (PMID: 25497253)
-
Contributed Indexing:
-
Keywords: fibroblast growth factor 23; general population; heart failure with preserved ejection fraction; heart failure with reduced ejection fraction
-
Substance Nomenclature:
-
0 (FGF23 protein, human)
7Q7P4S7RRE (Fibroblast Growth Factor-23)
-
Entry Date(s):
-
Date Created: 20220725 Date Completed: 20220803 Latest Revision: 20220920
-
Update Code:
-
20240105
-
PubMed Central ID:
-
PMC9375507
-
DOI:
-
10.1161/JAHA.121.024952
-
PMID:
-
35876420
-
Background The role of fibroblast growth factor 23 (FGF23) in the development of new-onset heart failure (HF) with reduced (HFrEF) or preserved ejection fraction (HFpEF) in the general population is unknown. Therefore, we set out to investigate associations of C-terminal FGF23 with development of new-onset HF and, more specifically, with HFrEF or HFpEF in a large, prospective, population-based cohort. Methods and Results We studied 6830 participants (aged 53.8±12.1 years; 49.7% men; estimated glomerular filtration rate, 93.1±15.7 mL/min per 1.73 m 2 ) in the community-based PREVEND (Prevention of Renal and Vascular End-Stage Disease) study who were free of HF at baseline. Cross-sectional multivariable linear regression analysis showed that ferritin (standardized β, -0.24; P <0.001) and estimated glomerular filtration rate (standardized β, -0.13; P <0.001) were the strongest independent correlates of FGF23. Multivariable Cox proportional hazard regression was used to study the association between baseline FGF23 and incident HF, HFrEF (ejection fraction ≤40%) or HFpEF (ejection fraction ≥50%). After median follow-up of 7.4 [IQR 6.9-7.9] years, 227 individuals (3.3%) developed new-onset HF, of whom 132 had HFrEF and 88 had HFpEF. A higher FGF23 level was associated with an increased risk of incident HF (fully adjusted hazard ratio, 1.29 [95% CI, 1.06-1.57]) and with an increased risk of incident HFrEF (fully adjusted hazard ratio, 1.31 [95% CI, 1.01-1.69]). The association between FGF23 and incident HFpEF lost statistical significance after multivariable adjustment (hazard ratio, 1.22 [95% CI, 0.87-1.71]). Conclusions Higher FGF23 is independently associated with new-onset HFrEF in analyses fully adjusted for cardiovascular risk factors and other potential confounders. The association between FGF23 and incident HFpEF lost statistical significance upon multivariable adjustment.